['tumor lysis syndrome']
['febuxostat']

        Inclusion Criteria:

          -  male and female children of 6 to less than 12 years of age, adolescents of 12 to less
             than 18 years of age and adults from 18 years:

          -  scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies

          -  and at intermediate or high risk of TLS

          -  and with no access to rasburicase

        Exclusion Criteria:

          -  patients with contraindications as per febuxostat summary of product characteristics

          -  patients with severe renal insufficiency

          -  patients with severe hepatic insufficiency

          -  patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)
      